Adial Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume40,244 shs
Average Volume224,402 shs
Market Capitalization$48.90 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Adial Pharmaceuticals logo

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.40 out of 5 stars

Medical Sector

1815th out of 2,099 stocks

Pharmaceutical Preparations Industry

754th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

What stocks does MarketBeat like better than Adial Pharmaceuticals?

Wall Street analysts have given Adial Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adial Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Adial Pharmaceuticals

How has Adial Pharmaceuticals' stock been impacted by Coronavirus?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADIL stock has increased by 100.0% and is now trading at $2.70.
View which stocks have been most impacted by COVID-19

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:
  • Mr. William B. Stilley III, M.B.A., MBA, Chairman, Pres & CEO (Age 53, Pay $614.1k)
  • Dr. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 61, Pay $375k)
  • Mr. Joseph M. Truluck M.B.A., MBA, CFO, COO, Treasurer & Sec. (Age 43, Pay $225.03k)
  • Dr. Jack W. Reich, Head of Regulatory (Age 72, Pay $17.01k)
  • Mr. Alex Lugovoy, Chief Bus. Officer
  • Mr. Mark H. Peikin, Chief Strategy Officer
  • Mr. Lawrence Goldman, Controller (Age 65)

Who are some of Adial Pharmaceuticals' key competitors?

What other stocks do shareholders of Adial Pharmaceuticals own?

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Private Advisor Group LLC (0.21%), Dimensional Fund Advisors LP (0.18%), Commonwealth Equity Services LLC (0.13%), Barclays PLC (0.09%), Rede Wealth LLC (0.09%) and Oppenheimer & Co. Inc. (0.08%). Company insiders that own Adial Pharmaceuticals stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends for Adial Pharmaceuticals

Which institutional investors are buying Adial Pharmaceuticals stock?

ADIL stock was bought by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, Barclays PLC, Rede Wealth LLC, Oppenheimer & Co. Inc., Dimensional Fund Advisors LP, and Commonwealth Equity Services LLC. Company insiders that have bought Adial Pharmaceuticals stock in the last two years include James W Jr Newman, and William B Stilley III.
View insider buying and selling activity for Adial Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.70.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals has a market capitalization of $48.90 million.

How many employees does Adial Pharmaceuticals have?

Adial Pharmaceuticals employs 8 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is

Where are Adial Pharmaceuticals' headquarters?

Adial Pharmaceuticals is headquartered at 1180 Seminole Trail Suite 495, Charlottesville VA, 22901.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at 434-422-9800 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.